A 22-year-old male with a history of difficult-to-treat bipolar disorder with psychotic features is undergoing a medication adjustment under the guidance of his psychiatrist. The patient was previously treated with lithium and is transitioning to clozapine. Which of the following tests will the patient need routinely?

Thyroid-stimulating hormone, prior to introducing the medication

Dexamethasone suppression test, monthly

A 28-year-old man is brought to the physician by his wife because she is worried about his unusual behavior. Two weeks ago, he was promoted and is now convinced that he will soon take over the firm. He has been working overtime at the office and spends most of his nights at parties. Whenever he comes home, he asks his wife to have sex with him and rarely sleeps more than 3 hours. He has a history of a similar episode and several periods of depression over the past 2 years. He currently takes no medications. He appears impatient, repeatedly jumps up from his seat, and says, "I have more important things to do." There is no evidence of suicidal ideation. Urine toxicology screening is negative. Long-term treatment with lithium is started. Which of the following endocrine parameters should be regularly monitored in this patient while he is undergoing treatment?

Serum thyroid-stimulating hormone

Complete blood count with differential

Medication monitoring protocols for USMLE Step 1: High-Yield CCS Cases Lessons

TDM Fundamentals - The "Just Right" Dose

Goal: Maintain drug plasma concentration within the therapeutic window to maximize efficacy and minimize toxicity.
Indicated for: Drugs with a Narrow Therapeutic Index (NTI) where effect is related to concentration.
Key Metrics:
- Trough ($C_{min}$): Lowest level, drawn just before the next dose. Monitors for toxicity.
- Peak ($C_{max}$): Highest level, drawn after administration. Assesses efficacy.

⭐ For most NTI drugs like Vancomycin and Aminoglycosides, trough concentration is the primary monitoring parameter to prevent dose-dependent toxicity.

Drug concentration over time: therapeutic range and MIC

The Usual Suspects - Rogues' Gallery of Drugs

*A quick reference for high-risk medication monitoring.

Drug Class / Agent	Key Monitoring Parameter(s) & Critical Thresholds
Anticoagulants
- Warfarin	INR (Target: 2.0-3.0 for most indications)
- UFH	aPTT (Target: 1.5-2.5x baseline)
Antiarrhythmics
- Amiodarone	TFTs, LFTs, PFTs (Baseline, then q6 months)
- Digoxin	Serum Level (Therapeutic: 0.5-0.9 ng/mL), Serum K+, Renal function
Psychotropics
- Lithium	Serum Level (Therapeutic: 0.6-1.2 mEq/L), TFTs, RFTs
- Clozapine	⚠️ ANC weekly for 6 months, bi-weekly for 6 months, then monthly.
Other High-Risk
- Methotrexate	CBC, LFTs, Creatinine (Baseline & periodic)
- Statins	LFTs (Baseline), CK (only if myalgia develops)

Warfarin & Digoxin - Heart-Watch Protocols

Warfarin (Oral Anticoagulant)
- Monitor: Prothrombin Time (PT) / International Normalized Ratio (INR).
- Target INR: 2.0-3.0 (standard); 2.5-3.5 (mechanical valves).
- Antidote: Vitamin K, Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrate (PCC).
- 📌 Mnemonic: WEPT → Warfarin, Extrinsic pathway, PT.
Digoxin (Cardiac Glycoside)
- Monitor: Serum digoxin levels (trough levels).
- Therapeutic Range: 0.8-2.0 ng/mL.
- Toxicity Risk: ↑ with hypokalemia, renal failure.
- Antidote: Digoxin Immune Fab (DigiFab).

⭐ Amiodarone significantly increases levels of both Warfarin (↑INR) and Digoxin; dose reduction is crucial.

Lithium & Antiepileptics - Brain-Balancer Surveillance

Lithium:
- Baseline: TFT, RFT, ECG.
- Therapeutic Level: 0.6-1.2 mEq/L. Check 12h post-dose, 5 days after start, then every 3-6 months.
- Toxicity >1.5 mEq/L. Monitor TFT/RFT annually.
- 📌 Mnemonic "LITH": Leukocytosis, Insipidus, Tremor, Hypothyroidism.
Key Antiepileptics:
- Valproate: Monitor LFTs (hepatotoxicity) & CBC.
- Carbamazepine: Monitor CBC (agranulocytosis). Screen Asians for HLA-B*1502 (SJS risk).
- Phenytoin: Watch for nystagmus & ataxia (toxicity).

⭐ In Asian populations, screening for the HLA-B*1502 allele is crucial before starting Carbamazepine to prevent Stevens-Johnson syndrome (SJS).

Therapeutic Drug Monitoring Cycle

High‑Yield Points - ⚡ Biggest Takeaways

Lithium requires regular monitoring of thyroid (TSH) and renal function tests (RFTs).

Clozapine mandates strict Absolute Neutrophil Count (ANC) monitoring due to high agranulocytosis risk.

For Valproate, periodically check liver function tests (LFTs) and complete blood count (CBC).

Amiodarone necessitates baseline and periodic TFTs, LFTs, and chest X-rays/PFTs.

Warfarin/Acenocoumarol therapy is closely guided by PT/INR to prevent bleeding or thrombosis.

Methotrexate requires routine checks of CBC, LFTs, and RFTs.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play

Medication monitoring protocols